PinCell
4.5.2023 10:01:39 CEST | ACCESS Newswire | Press release
Proprietary transgenic mouse produces human form of FasL protein
MILAN, ITALY / ACCESSWIRE / May 4, 2023 / PinCell, a biotechnology company developing a first-in-class therapy for rare and debilitating autoimmune skin diseases, announced the successful completion of two independent in-vivo studies of its lead candidate (PC111) using a proprietary transgenic mouse model expressing the human form of the target protein (FasL). PinCell is a spin-off of the University of Modena and Reggio Emilia and was seed financed by Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.PinCell's monoclonal antibody, PC111, proved effective in the neonatal passive pemphigus mouse model, considered the gold standard for testing treatments of pemphigus, a rare and debilitating skin disease marked by extreme blistering of skin and mucosae. Using the proprietary transgenic mouse, PC111 inhibited the production of blisters by at least 80%, confirming previous studies in in-vitro and ex-vivo human models of pemphigus. PC111 was also shown to dose-dependently neutralize human FasL in another in-vivo setting involving the Concanavalin-A liver model, which induces an acute release of FasL into the blood.
"This is a great achievement for the company," said Dr. Antonino (Tony) Amato, Chief Executive Officer of PinCell. "It provides for the first time in-vivo proof of concept evidence of PC111 effect in a humanized disease setting."
"We feel a real sense of accomplishment," said Prof. Carlo Pincelli, founder and Chief Medical Officer at PinCell. "By developing a proprietary model, we have now shown that our antibody does indeed inhibit blister formation by binding specifically to the human target."
"What is more, the humanized FasL mouse model could prove to be a valuable tool to study the involvement of the Fas/FasL pathway in other diseases in which this pathway may play a key role in disease development and progression," Prof. Pincelli added.
About pemphigus
Pemphigus is a rare condition that affects about 300,000 patients worldwide. Conservatively, a treatment based on PC111 would be beneficial for over 30 percent of this population who are relapsing or refractory to first line treatments.
PinCell's therapy will be an alternative to steroids or immunosuppressants currently prescribed or under development. By acting downstream from the immune system, at the level of skin cells, PC111's innovative mode of action will contribute to the reduction or the avoidance of steroids/immunosuppressants, while showing a rapid onset of action.
About PinCell
PinCell is a biotechnology company targeting a novel pathological pathway to develop first-in-class anti-inflammatory therapies for the treatment of rare, severe and highly undertreated skin diseases. Based in Milan, Italy, PinCell was founded in October 2008 as an academic spin-off of the University of Modena and Reggio Emilia by the world-class dermatology experts Prof. Carlo Pincelli and Prof. Alessandra Marconi. PinCell received seed funding from Sofinnova Partners.
For more information, please visit: www.pincell.it
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: sofinnovapartners.com
CONTACT: Tony Amato, MD - CEO, PinCell - a.amato@pincell.com - +39-334-6263471
SOURCE: PinCell
View source version on accesswire.com:
https://www.accesswire.com/752528/PinCell-Announces-2-Successful-In-Vivo-Studies-for-Breakthrough-Skin-Disease-Therapy
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Valsoft's TAG Software Group Enters the Content Operations Market with the Acquisition of Chalco6.11.2026 16:25:00 CET | Press release
MONTRÉAL, QC / ACCESS Newswire / November 6, 2026 / Valsoft Corporation Inc. ("Valsoft"), a Canadian company specializing in the acquisition and long-term development of vertical market software businesses, today announced the acquisition of 100% of Chalco, a software platform for managing the full lifecycle of product content and information, from Hyphen-Group. The deal marks Valsoft's entry into the content operations market, a fast-growing space that is increasingly critical to organizational growth in the age of AI, and brings the number of industries in which Valsoft operates to more than 20. The acquisition was completed by TAG Software Group through Chalco Technologies Srl ("Chalco Technologies"), a newly formed company wholly owned by Valsoft. Chalco was developed within Hyphen-Group, an Italian company active in the content operations market for more than 25 years, with offices in Affi (Verona), Milan, and Lugano, Switzerland, and a client base that includes some of the world'
Innodata Reports Record Third Quarter 2026 Results5.11.2026 22:05:00 CET | Press release
NEW YORK, NY / ACCESS Newswire / November 5, 2026 / INNODATA INC. (Nasdaq:INOD) today reported results for the third quarter ended September 30, 2026.Revenue of $95.6 million, representing 53% year-over-year revenue growth.Adjusted Gross Profit of $38.3 million, representing Adjusted Gross Margin of 40%.*Adjusted EBITDA of $17.7 million, or 18.5% of revenue, an increase of $1.5 million from $16.2 million in the same period last year.*Net income of $10.3 million, or $0.30 per basic share and $0.29 per diluted share for the three-month period ended September 30, 2026, compared to net income of $8.3 million, or $0.26 per basic share and $0.24 per diluted share, in the same period last year.Cash and cash equivalents of $164.0 million as of September 30, 2026, an increase of $81.7 million from $82.2 million as of December 31, 2025. Cash as of September 30, 2026 includes customer prepayments related to pass-through costs; net of these prepayments, cash was approximately $153.7 million as of
MicroVision and LAKE FUSION Technologies Sign Multi-Year Strategic Partnership Agreement for IRIS(TM) Lidar Sensors5.11.2026 15:20:00 CET | Press release
ORLANDO, FL AND MARKDORF, GERMANY / ACCESS Newswire / November 5, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception solutions for industrial, security and defense, intelligent infrastructure, and automotive mobility, today announced a multi-year strategic partnership agreement with LAKE FUSION Technologies (LFT), a German developer of advanced sensor fusion and situational awareness systems. Under the agreement, LFT has committed to purchasing MicroVision IRIS™ long-range lidar sensors throughout 2027 and into 2028 for integration into its Awareness Systems (AS-1), designed to enhance safety and obstacle detection for civil and military helicopter operations. The multi-year agreement marks another significant commercial milestone following the companies' June 2026 announcement to expedite the integration of IRIS lidar technology and accelerate the deployment of advanced situational awareness solutions. With testing and evaluation progressing into a formal strategi
Chervon Names Doug Palmer Vice President of Finance - Canada5.11.2026 15:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / November 5, 2026 / Effective November 9, 2026, Chervon names Doug Palmer Vice President of Finance - Canada, reporting to Neil Harrison, Vice President and Managing Director of Chervon Canada. He will also have a dotted-line reporting relationship to Ryan Wang, Chief Financial Officer, Chervon NA. Palmer brings to Chervon an exceptional 20-year career of increasingly responsible positions in Canadian financial management. During his 18-year career at J.M. Smucker, he held financial management positions as Analyst, Senior Manager, Director, and Senior Director, responsible for all elements of financial control and FP&A. Most recently, he served as Vice President of Finance at the Crump Group. "We have identified Canada as a strategic priority for Chervon with massive growth potential," said Joe Galli, Chervon CEO. "We are building the best leadership team in the Power Tool and OPE industry in Canada. Doug Palmer is an outstanding addition to this high-per
New EuroFinance Study, Sponsored by TIS, Puts Treasury at the Center of Cybersecurity5.11.2026 15:00:00 CET | Press release
BERLIN, DE / ACCESS Newswire / November 5, 2026 / New Deep Dive research, Cyber Risk Management: No Longer Just an IT Problem, finds that cyber risk is increasingly disrupting payments, liquidity management, and business continuity. Sponsored by TIS, a global leader in payments and cash management technology, the new report extracts insights from treasury and cybersecurity professionals across housing, commodities, manufacturing, consumer goods, and telecommunications who agree that cybersecurity is a growing treasury and liquidity risk. Why Treasury Is at the Center of Cyber Risk The ongoing digitization of the treasury ecosystem through APIs, cloud platforms, and automation has increased the speed and efficiency of treasury operations. While treasury teams are moving faster, their exposure to sophisticated cyber threats, including deepfake videos, fraudulent invoices, and manipulating approvals through compromised digital channels, has expanded in proportion. These threats most frequ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom